Cargando…

Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma

Epigenetic mechanisms which play an essential role in normal developmental processes, such as self-renewal and fate specification of neural stem cells (NSC) are also responsible for some of the changes in the glioblastoma (GBM) genome. Here we develop a strategy to compare the epigenetic and transcr...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinel, Claire, Rosser, Gabriel, Guglielmi, Loredana, Constantinou, Myrianni, Pomella, Nicola, Zhang, Xinyu, Boot, James R., Jones, Tania A., Millner, Thomas O., Dumas, Anaelle A., Rakyan, Vardhman, Rees, Jeremy, Thompson, Jamie L., Vuononvirta, Juho, Nadkarni, Suchita, El Assan, Tedani, Aley, Natasha, Lin, Yung-Yao, Liu, Pentao, Nelander, Sven, Sheer, Denise, Merry, Catherine L. R., Marelli-Berg, Federica, Brandner, Sebastian, Marino, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531305/
https://www.ncbi.nlm.nih.gov/pubmed/34675201
http://dx.doi.org/10.1038/s41467-021-26297-6
Descripción
Sumario:Epigenetic mechanisms which play an essential role in normal developmental processes, such as self-renewal and fate specification of neural stem cells (NSC) are also responsible for some of the changes in the glioblastoma (GBM) genome. Here we develop a strategy to compare the epigenetic and transcriptional make-up of primary GBM cells (GIC) with patient-matched expanded potential stem cell (EPSC)-derived NSC (iNSC). Using a comparative analysis of the transcriptome of syngeneic GIC/iNSC pairs, we identify a glycosaminoglycan (GAG)-mediated mechanism of recruitment of regulatory T cells (Tregs) in GBM. Integrated analysis of the transcriptome and DNA methylome of GBM cells identifies druggable target genes and patient-specific prediction of drug response in primary GIC cultures, which is validated in 3D and in vivo models. Taken together, we provide a proof of principle that this experimental pipeline has the potential to identify patient-specific disease mechanisms and druggable targets in GBM.